Skip to main content
Premium Trial:

Request an Annual Quote

Icoria Q4 2004 Revenues Up 15.6 Percent; 2004 Receipts Still Below Expectations

NEW YORK, March 24 (GenomeWeb News) - Icoria today reported fourth-quarter 2004 revenue of $6.3 million, up 15.6 percent from $5.5 million in the same quarter of 2003, according to documents filed with the US Securities and Exchange Commission today.

 

Total revenue for 2004 was $24.6 million, up $3.5 million from $21.1 million in 2003, but the numbers were below what Icoria was hoping for. "While we achieved record revenue in 2004, it was below our expectations, largely due to a lack of new commercial activity in quantitative analytics," Heinrich Gugger, Icoria president and CEO, said today in a statement.

 

Research and development expenses for the recent quarter were $6.1 million, compared to $1.7 million in the fourth quarter of 2003.

 

Icoria's fourth-quarter 2004 net loss jumped to $4.1 million, or $.11 per share, from $2.2 million, or $.07 per share, in the similar quarter in 2003.

 

The company's cash, cash equivalents, and short-term investments amounted to $9.6 million as of December 31.

 

Separately today, Icoria announced the sale of its agricultural genomics assets to Monsanto for $6.75 million in order to reposition itself as a biomarker-discovery company, the firm said.

 

Monsanto, which will get Icoria's Research Triangle Park, NC, facility in the deal, paid $4.75 million up front for the assets, with the remainder to be paid in January 2006, Icoria said.

 

Icoria, formerly known as Paradigm Genetics, said it expects to reduce its headcount by 70 staffers by the end of the second quarter, bringing headcount to 120. It added that 60 of these employees are expected to join Monsanto. Additional lay-offs occurred at Icoria's Pittsburghoffices, the company said.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.